286 related articles for article (PubMed ID: 30626790)
1. [Blastic plasmacytoid dendritic cell neoplasm accompanied by chronic myelomonocytic leukemia successfully treated with azacitidine].
Sukegawa S; Sakata-Yanagimoto M; Matsuoka R; Momose H; Kiyoki Y; Noguchi M; Nakamura N; Watanabe R; Fujimoto M; Yokoyama Y; Nishikii H; Kato T; Kusakabe M; Kurita N; Obara N; Hasegawa Y; Chiba S
Rinsho Ketsueki; 2018; 59(12):2567-2573. PubMed ID: 30626790
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients.
Khanlari M; Yin CC; Takahashi K; Lachowiez C; Tang G; Loghavi S; Bah I; Wang W; Konoplev S; Medeiros LJ; Pemmaraju N; Khoury JD; Wang SA
Leukemia; 2022 May; 36(5):1343-1350. PubMed ID: 35279700
[TBL] [Abstract][Full Text] [Related]
3. Blastic plasmacytoid dendritic cell neoplasm with a history of cytopenia: A case report.
Yan M; Wang W; Cen X; Wang L; Sun Y; Wang B; Ou J; Nong L; Ren H; Zhu P; Wang M
Diagn Cytopathol; 2020 Nov; 48(11):1102-1106. PubMed ID: 32374950
[TBL] [Abstract][Full Text] [Related]
4. Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review.
Samhouri Y; Ursu S; Dutton N; Tanvi V; Fazal S
J Oncol Pharm Pract; 2021 Jun; 27(4):990-995. PubMed ID: 32847479
[TBL] [Abstract][Full Text] [Related]
5. Blastic plasmacytoid dendritic-cell neoplasia: a challenging case report.
Koerber RM; Held SAE; Vonnahme M; Feldmann G; Wenzel J; Gütgemann I; Brossart P; Heine A
J Cancer Res Clin Oncol; 2022 Mar; 148(3):743-748. PubMed ID: 34529129
[TBL] [Abstract][Full Text] [Related]
6. Low-dose venetoclax combined with azacitidine for blastic plasmacytoid dendritic cell neoplasm: a case report and literature review.
Wang Q; Zhao Y; Zang X; Zhou G; Liu Y; Feng Q; Li X; Wang W; Dong X; Liu X; Peng J; Liu C
Ann Hematol; 2024 Mar; 103(3):999-1005. PubMed ID: 38285081
[TBL] [Abstract][Full Text] [Related]
7. Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Beird HC; Khan M; Wang F; Alfayez M; Cai T; Zhao L; Khoury J; Futreal PA; Konopleva M; Pemmaraju N
Blood Cancer J; 2019 Dec; 9(12):99. PubMed ID: 31811114
[TBL] [Abstract][Full Text] [Related]
8. Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia.
Berg JL; Perfler B; Hatzl S; Mayer MC; Wurm S; Uhl B; Reinisch A; Klymiuk I; Tierling S; Pregartner G; Bachmaier G; Berghold A; Geissler K; Pichler M; Hoefler G; Strobl H; Wölfler A; Sill H; Zebisch A
Clin Epigenetics; 2021 Jan; 13(1):1. PubMed ID: 33407852
[TBL] [Abstract][Full Text] [Related]
9. Specific skin lesions in chronic myelomonocytic leukemia: a spectrum of myelomonocytic and dendritic cell proliferations: a study of 42 cases.
Vitte F; Fabiani B; Bénet C; Dalac S; Balme B; Delattre C; Vergier B; Beylot-Barry M; Vignon-Pennamen D; Ortonne N; Algros MP; Carlotti A; Samaleire D; Frouin E; Levy A; Laroche L; Theate I; Monnien F; Mugneret F; Petrella T
Am J Surg Pathol; 2012 Sep; 36(9):1302-16. PubMed ID: 22895265
[TBL] [Abstract][Full Text] [Related]
10. Blastic plasmacytoid dendritic cell neoplasm with leukemic manifestation and ETV6 gene rearrangement: A case report.
Gao NA; Wang XX; Sun JR; Yu WZ; Guo NJ
Exp Ther Med; 2015 Apr; 9(4):1109-1112. PubMed ID: 25780395
[TBL] [Abstract][Full Text] [Related]
11. Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia.
Loghavi S; Curry JL; Garcia-Manero G; Patel KP; Xu J; Khoury JD; Torres-Cabala CA; Nagarajan P; Aung PP; Gibson BR; Goodwin BP; Kelly BC; Korivi BR; Medeiros LJ; Prieto VG; Kantarjian HM; Bueso-Ramos CE; Tetzlaff MT
J Cutan Pathol; 2017 Dec; 44(12):1075-1079. PubMed ID: 28885734
[TBL] [Abstract][Full Text] [Related]
12. Venetoclax Combined with Azacytidine Can Be a First-line Treatment Option for Elderly Blastic Plasmacytoid Dendritic Cell Neoplasm.
Nagate Y; Nakaya A; Kamimura R; Hirose Y; Nojima S; Fujita J; Kiyohara E; Shibayama H
Intern Med; 2023; 62(17):2547-2551. PubMed ID: 37661416
[TBL] [Abstract][Full Text] [Related]
13. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
[TBL] [Abstract][Full Text] [Related]
14. Blastic plasmacytoid dendritic cell neoplasm with genetic mutations in multiple epigenetic modifiers: a case report.
Dang X; Zhou D; Meng L; Bi L
J Int Med Res; 2021 Feb; 49(2):300060520982667. PubMed ID: 33530792
[TBL] [Abstract][Full Text] [Related]
15. Unique presentation of blastic plasmacytoid dendritic cell neoplasm: a single-center experience and literature review.
Paluri R; Nabell L; Borak S; Peker D
Hematol Oncol; 2015 Dec; 33(4):206-11. PubMed ID: 24850172
[TBL] [Abstract][Full Text] [Related]
16. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow.
Alayed K; Patel KP; Konoplev S; Singh RR; Routbort MJ; Reddy N; Pemmaraju N; Zhang L; Shaikh AA; Aladily TN; Jain N; Luthra R; Medeiros LJ; Khoury JD
Am J Hematol; 2013 Dec; 88(12):1055-61. PubMed ID: 23940084
[TBL] [Abstract][Full Text] [Related]
17. Blastic Indeterminate Dendritic Cell Tumor Associated With Chronic Myelomonocytic Leukemia.
Ellis A; Elbaz Younes I; Shao H; Zhang X
Am J Dermatopathol; 2022 Sep; 44(9):691-695. PubMed ID: 35476037
[TBL] [Abstract][Full Text] [Related]
18. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy.
Riaz W; Zhang L; Horna P; Sokol L
Cancer Control; 2014 Oct; 21(4):279-89. PubMed ID: 25310209
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia.
Cull AH; Mahendru D; Snetsinger B; Good D; Tyryshkin K; Chesney A; Ghorab Z; Reis M; Buckstein R; Wells RA; Rauh MJ
Leuk Res; 2018 Feb; 65():5-13. PubMed ID: 29227812
[TBL] [Abstract][Full Text] [Related]
20. Molecular Features of Blastic Plasmacytoid Dendritic Cell Neoplasm: DNA Mutations and Epigenetics.
Sapienza MR; Pileri S
Hematol Oncol Clin North Am; 2020 Jun; 34(3):511-521. PubMed ID: 32336416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
